Journal article

Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults

Rachel F Buckley, Elizabeth C Mormino, Jennifer S Rabin, Timothy J Hohman, Susan Landau, Bernard J Hanseeuw, Heidi IL Jacobs, Kathryn V Papp, Rebecca E Amariglio, Michael J Properzi, Aaron P Schultz, Dylan Kirn, Matthew R Scott, Trey Hedden, Michelle Farrell, Julie Price, Jasmeer Chhatwal, Dorene M Rentz, Victor L Villemagne, Keith A Johnson Show all

JAMA Neurology | AMER MEDICAL ASSOC | Published : 2019

Grants

Awarded by National Institutes of Health


Awarded by Center for Functional Neuroimaging Technologies (National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health)


Awarded by High-End Instrumentation Grant Program


Awarded by Alzheimer's Disease Neuroimaging Initiative (National Institutes of Health)


Awarded by US Department of Defense ADNI


Funding Acknowledgements

Some data used in the preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (http://adni.loni.usc.edu). The ADNI was launched in 2003 as a public-private partnership, led by principal investigator Michael W. Weiner, MD. The primary goal of ADNI has been to test whether serial magnetic resonance imaging, positron emission tomography, other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment and early Alzheimer disease. For up-to-date information, see www.adni-info.org.This work was supported with funding from the National Institutes of Health (grants P01 AG036694 [Drs Sperling and Johnson], R01 AG053509 [Dr Hedden], P50 AG005134 [Drs Sperling, Johnson, and Hedden], K23 AG049087 [Dr Chhatwal], and K24 AG035007 [Dr Sperling]). This research was carried out in part at the Athinoula A. Martinos Center for Biomedical Imaging at the Massachusetts General Hospital, using resources provided by the Center for Functional Neuroimaging Technologies (grant P41EB015896, a P41 Biotechnology Resource Grant supported by the National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health). This work also involved the use of instrumentation supported by the National Institutes of Health Shared Instrumentation Grant Program and/or High-End Instrumentation Grant Program (grants S10RR021110, S10RR023401, and S10RR023043). For ADNI, data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (National Institutes of Health grant U01 AG024904) and US Department of Defense ADNI (award W81XWH-12-2-0012). The Alzheimer's Disease Neuroimaging Initiative is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from AbbVie; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica Inc; Biogen; Bristol-Myers Squibb; CereSpir Inc; Cogstate; Eisai Inc; Elan Pharmaceuticals Inc; Eli Lilly; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech; Fujirebio; GE Healthcare; IXICO Ltd; Janssen Alzheimer Immunotherapy Research & Development; Johnson & Johnson Pharmaceutical Research & Development; Lumosity; Lundbeck; Merck & Co; Meso Scale Diagnostics; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals; Pfizer; Piramal Imaging; Servier; Takeda Pharmaceutical; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical facilitated by the Foundation for the National Institutes of Health (http://www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. Alzheimer's Disease Neuroimaging Initiative data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.